Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Immunocore (IMCR) with an Overweight rating and $60 price target The firm believes Kimmtrak “provides a good floor value” for the stock and indication expansion opportunities could offer upside over the next 12 months. There is room for further penetration, especially in the community setting, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore’s Innovative Approach: A New Hope for PRAME-Positive Cancer Treatment
- Immunocore’s Phase 3 Melanoma Study: A Potential Game Changer?
- Immunocore’s Promising Melanoma Study: A Potential Game-Changer
- Immunocore’s Brenetafusp: A Promising Study in PRAME-Positive Cancers
- Immunocore’s Innovative Cancer Study: A Potential Game-Changer for Investors